Biotherapies for Life
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information visit at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
CytoSorbents is a critical care immunotherapy company commercializing its CE approved CytoSorb, a safe and effective cytokine adsorber. CytoSorb is designed to attenuate the dysregulated, hyperinflammatory response („cytokine storm“) present in septic shock and other, non-infectious systemic hyperinflammatory states by reducing elevated levels of cytokines and other inflammatory mediators. This modulation of the immune response can lead to an improvement of hemodynamics, a reduction in the need for vasopressors and overall to an increased chance for recovery of organ functions and improved patient outcomes. CytoSorb is indicated in various hyperinflammatory states of infectious and non-infectious origin, e.g. after cardiac surgery, in cardiogenic shock, trauma, burns, pancreatitis and infection. So far it has been used safely and well tolerated in more than 27,000 single treatments worldwide. CytoSorb Therapy – REGAIN CONTROL!